Jazz Pharmaceuticals plc · JAZZ · FY2026 Q3 · Calendar Q4 2026
Jazz lifts 2026 revenue outlook as Ziihera launch adds momentum
The quarter strengthens the case that Jazz’s commercial portfolio can support growth: record revenue, continuing Xywav expansion and Ziihera’s early launch accompanied a higher 2026 revenue outlook. The durability of that trajectory depends on execution across new oncology uptake and established products facing competition.
Earnings scorecard
Reported versus consensusMarket reaction
close-to-close (session unavailable)Ask FN2 about JAZZ FY2026 Q3
Transcript, numbers and history already loadedFree account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior-quarter analysis, management’s outlook moved from a $4.60–$4.75 billion full-year revenue range to $4.775–$4.85 billion for 2026. Ziihera has since received FDA approval and entered launch, while the Actio acquisition added ABS-1230 to the rare-epilepsy pipeline.
Guidance delta
Raised: 2026 revenue guidance is $4.775–$4.85 billion, versus $4.60–$4.75 billion in the prior-quarter analysis.
Key takeaways
- Q3 revenue reached a record $1.24 billion, up 10% year over year, according to the supplied transcript analysis.
- Management cited 12% growth in Xywav and strong oncology performance.
- Ziihera’s FDA approval and early launch are central to the next phase of commercial execution.
- Actio adds ABS-1230, alongside several clinical and formulation milestones ahead.
Management priorities
- Build Ziihera adoption in first-line HER2-positive metastatic GEA, including community-setting uptake.
- Sustain Xywav growth while monitoring generic high-sodium oxybate effects.
- Advance pipeline milestones, including ABS-1230, ACTION and EmpowHER-303.
- Expand cannabidiol access through the proposed oral capsule formulation.
Follow JAZZ with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeCompany context
Snapshot as of publicationJazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease.…
Healthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical Inc. | FY2026 Q3 · Calendar Q4 2026 | +376.0% | -1.8% | BioMarin’s Q3 growth meets a lower full-year outlook |
| IDXX IDEXX Laboratories, Inc. | FY2026 Q3 · Calendar Q4 2026 | +6.2% | +21.8% | IDEXX Raises FY2026 Outlook on Diagnostics and Software Growth |
| NBIX Neurocrine Biosciences, Inc. | FY2026 Q3 · Calendar Q4 2026 | +72.3% | -0.5% | Neurocrine Raises INGREZZA Outlook as Core Products Grow |
| AXSM Axsome Therapeutics, Inc. | FY2026 Q3 · Calendar Q4 2026 | +60.6% | -5.8% | Axsome’s Q3 growth broadens, while reimbursement and trial execution remain key tests |
| TEM Tempus AI, Inc. | FY2026 Q3 · Calendar Q4 2026 | +174.7% | +8.7% | Tempus Q3 growth broadens across diagnostics and data |
| SNY Sanofi | FY2026 Q3 · Calendar Q4 2026 | +30.8% | +2.8% | Sanofi lifts 2026 outlook as Dupixent and launches drive Q3 growth |
Latest beats and misses
Who reports nextBeat on EPS
Missed on EPS
- PEGFY2026 Q3 · November 2, 2026-3.4% EPS+0.1% move
- RYAAYFY2027 Q2 · November 2, 2026-0.3% EPS+2.9% move
- GLPIFY2026 Q3 · October 29, 2026-11.5% EPS-1.3% move
- LYBFY2026 Q3 · October 30, 2026-1.2% EPS+5.0% move
- CCJFY2026 Q3 · October 30, 2026-101.4% EPS-7.9% move
- VALEFY2026 Q3 · October 29, 2026-24.6% EPS+1.9% move
Get the JAZZ recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-11-03T04:07:36.833765+00:00
- FN2 earnings calendar · 2026-11-03T01:23:13.143323+00:00
- Polygon adjusted daily market bars · 2026-11-03T06:40:44.821305+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-03T06:40:44.818612+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-11-03. For educational purposes only; not investment advice.